Ipsen Announces Data Presentations of Cabozantinib (Cabometyx™), Lanreotide (Somatuline® Autogel®) and Telotristat Ethyl* at the European Society for Medical Oncology (ESMO) 2016 Congress
PARIS–(BUSINESS WIRE)– Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven pharmaceutical group, today announced that Cabometyx™ (cabozantinib), Somatuline® Autogel® (lanreotide) and telotristat ethyl (*previously known...